We analyzed the factors associated with plasma EGFR mutation detection and the effect of plasma EGFR genotyping on the clinical outcomes of the patients with treatment-naïve stage IV NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.